



2027-28

Pharmaceutical Industry Fellowship Program



Table of Contents

A Message from our President and CEO	2
Company Overview	3
Global Values and Vision	4
Portfolio Overview	5
Extensive History in Infectious Disease	6
U.S. Pipeline: Infectious Disease, Rare Disease and Areas of High Unmet Medical Need	7
Shionogi Inc. Leadership Team	8
Serving Patients Around the World	10
Program Overview	11
Meet Our Inaugural Fellow.	12
U.S. Medical Affairs Executive Sponsor and Preceptor	13
Shionogi Inc. U.S. Medical Affairs Fellowship: Year 1	14
Market Access Executive Sponsor and Preceptor	15
Shionogi Inc. Market Access Fellowship: Year 2	16
Rutgers Pharmaceutical Industry Fellowship Program	17



Dear Prospective Fellows,

Thank you for taking the time to learn about Shionogi Inc. and our participation in the Rutgers University Pharmaceutical Industry Fellowship (RPIF) Program. Our second year in this esteemed program reflects the continued growth and momentum of our U.S. organization and reinforces our commitment to fostering future leaders in the pharmaceutical industry.

Shionogi & Co., Ltd., our parent company, was founded in Japan nearly 150 years ago. Since the 1950s, we have discovered and introduced several novel antibiotics, as well as innovative medications for HIV and influenza. Today, our global presence includes operations across Asia, Europe, the U.S. and Canada. In the U.S., our pipeline includes clinical programs for infectious disease, including antivirals, antibiotics and antifungals, rare disease, oncology and other areas with high unmet medical needs.

We designed the fellowship program to offer a diverse and immersive cross-functional experience. Through the program, you will spend one year embedded in our U.S. Medical Affairs team and one year integrated with our U.S. Market Access team.

During the Medical Affairs rotation, you will help shape medical strategies, drive data generation and dissemination initiatives, and collaborate with

scientific and patient advocacy organizations. You will work closely with multiple global cross-functional teams and gain tangible skills to support career growth.

As part of the Market Access program, you will help generate health economic data, while building a comprehensive understanding of the key market access policies impacting the pharmaceutical industry.

We have developed a program that not only provides a truly immersive experience, but also one that will prepare you to lead and succeed in increasingly complex global environments.

I believe you will find RPIF Program at Shionogi to be as unique as our company and our culture, and I hope you will take the time to learn more about us in the following pages.

Best wishes for a successful recruitment process.



Nathan McCutcheon
President and CEO
Shionogi Inc.



Company Overview

Since 1878, Shionogi has been harnessing the full potential of science to treat challenging human diseases. Our discoveries have led to new treatment options that have improved the lives of patients worldwide. Throughout our history, we have remained true to our founding principle — to supply the best possible medicines to protect the health and well-being of the patients we serve.

Our expertise in infectious disease dates back to the 1950s. Today, building on a legacy of discovering and developing innovative antibiotics, our global portfolio includes approved and investigational antibiotics, antivirals for COVID-19, HIV and influenza, and a therapeutic for rare fungal infections.

Our U.S. infectious disease franchise includes approved and investigational novel anti-infectives, as well as approved and investigational antivirals

for COVID-19 and an investigational antiviral for RSV. In parallel, we are advancing a U.S. rare disease franchise that includes an approved therapy for amyotrophic lateral sclerosis (ALS), along with clinical programs in Fragile X syndrome, Jordan's syndrome and Pompe disease. We are also pursuing research in additional high-unmet need therapeutic areas, including oncology, acute ischemic stroke and sleep apnea.

Our team is driven to impact patient lives. Our partnerships with industry, government agencies and academia help to advance science with the urgency that today's health challenges demand. Through a combination of in-house discovery and strategic partnerships, we continue to deliver firsts for patients in the U.S. and worldwide.



Global Values and Vision

We are committed to supplying the best possible medicines to aid the health and well-being of the patients we serve. We believe that to achieve this vision, we must collectively embody the following values.



Be Trustworthy

Pursue honesty, accuracy, fairness and transparency to earn and retain society's trust.



Boldness and Innovation

Drive needed change by identifying, understanding and rapidly leading innovative new approaches that anticipate the future needs of our organization and industry.



Play to Win

Aim high, be competitive, never give up and strive to achieve goals the right way.



Respect for Diversity

Appreciate different and diverse viewpoints, create teams that make each other better.



Contribution to Society

Contribute to society by addressing unmet needs and supplying the best possible solutions.

Portfolio Overview

Shionogi is committed to identifying unmet needs and harnessing the full potential of science to treat challenging human diseases. Our discoveries have led to the development of new treatments that have improved patients' lives worldwide.

2003 Shionogi developed CRESTOR® (rosuvastatin calcium), a hyperlipidemia treatment, and licensed it to AstraZeneca to commercialize worldwide. In 2020, Grünenthal acquired market rights in more than 30 European countries, not including Spain and the UK.

2013 Alongside GlaxoSmithKline (GSK) and Pfizer, we are collaborating with ViiV Healthcare to produce vital medicines for treating and preventing HIV/AIDS. Our collaboration has produced several treatment options over the last decade, including dolutegravir and cabotegravir.

2015 Symproic® (naldemedine) was developed by Shionogi for patients with opioid-induced constipation. It is out-licensed in the U.S. through BioDelivery Sciences International, Inc., a wholly owned subsidiary of Collegium.

2018 Shionogi developed Xofluza® (baloxavir marboxil), an influenza medication, in a license and collaboration agreement with the Roche Group. It is commercialized by Roche in the U.S.

2020 Shionogi launched in-house discovered Fetroja® (cefiderocol), an innovative siderophore cephalosporin, in the U.S.


2026 Shionogi expanded its rare disease franchise with the acquisition of all rights to RADICAVA (edaravone) for the treatment of ALS in major countries and regions.

2026 Shionogi launched in-house discovered XOCOVA® (ensitrelvir) for post-exposure prophylaxis of COVID-19 in the U.S.



Extensive History in Infectious Disease

Since 1953, there have been many global advancements in infectious disease innovation, and Shionogi has been a pioneer in making critical infectious disease medicines available in Japan and across Asian markets.



○ Discovered by Shionogi

● Commercialized by Shionogi

◉ Discovered and commercialized by Shionogi

* Commercialized in Japan in 2022 and in the U.S. in 2026

U.S. Pipeline: Infectious Disease, Rare Disease and Areas of High Unmet Medical Need

Shionogi has a long history of small molecule drug discovery. Our current pipeline includes projects across several therapeutic areas, including infectious disease. We are advancing clinical programs for infectious disease, rare disease, acute ischemic stroke and oncology.

Phase 1	Phase 2	Phase 3	Filing	Phase 4
Fetroja® (cefiderocol) Cell-Wall Synthesis Inhibitor	Focus: Infections Due to Gram-Negative Bacteria in Pediatric Patients Delivery: Intravenous Infusion Origin: In-House Development: In-House			
Zatolmilast Selective PDE4D Inhibitor	Focus: Fragile X Syndrome		Delivery: Oral	Origin: Tetra Therapeutics (USA) Development: In-House
	Focus: Jordan's Syndrome		Delivery: Oral	Origin: Tetra Therapeutics (USA) Development: In-House
Redasemtide Trifluoroacetate Endogenous Stem Cell Mobilization	Focus: Acute Ischemic Stroke		Delivery: Intravenous Infusion	Origin: StemRIM (Japan) Development: In-House
Secutrelvir 3CL Protease Inhibitor	Focus: COVID-19		Delivery: Oral (Treatment)	Origin: In-house Development: In-House
	Focus: COVID-19		Delivery: Long-Acting Injectable (Pre-Exposure Prophylaxis)	Origin: In-House Development: In-House
S-337395 RNA-Dependent RNA Polymerase Inhibitor	Focus: Respiratory Syncytial Virus		Delivery: Oral	Origin: In-House/UBE Development: In-House/UBE
S-531011 Anti-CCR8 Antibody	Focus: Solid Tumors		Delivery: Intravenous Infusion	Origin: In-House Development: In-House
S-606001 Glycogen Synthase 1 Inhibitor	Focus: Pompe Disease		Delivery: Oral	Origin: Maze Therapeutics Development: In-House
S-649228 Xeruborbactam + Cefiderocol	Focus: Infections Due to Gram-Negative Bacteria		Delivery: Intravenous Infusion	Origin: Qpex Development: In-House
S-054501 S-600918 + Combination Medicine	Focus: Sleep Apnea with a Central Component		Delivery: Oral	Origin: In-House/Apnimed Development: In-House
S-054502 Sulthiame	Focus: Sleep Apnea		Delivery: Oral	Origin: In-House/Apnimed Development: In-House

These compounds and their uses are investigational and have not all been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview and should not be construed as a recommendation for use of any product for unapproved uses.

Shionogi Inc. Leadership Team

The Shionogi Inc. leadership team has decades of combined pharmaceutical and industry experience in developing and commercializing therapeutics.



Nathan McCutcheon, MBA
President and Chief Executive Officer



Margaret Borys, MBA
EVP and Chief Commercial Officer



Tadashi Hara
EVP and Chief Global Operations Officer



David Benadon
SVP and Chief Human Resources Officer



Masahiro Fujita
SVP and Chief Financial Officer



Chris Klein
SVP and General Counsel

Shionogi Inc. Leadership Team (Continued)



Jason Banks, Ph.D.
VP, Clinical Operations



Lynn Dale
SVP, Supply Chain



Florin Draica, MD, CMD, MBA
VP, Medical Affairs



Ann Howell, Pharm.D., MS
SVP, Global Head Regulatory Affairs



Shouko Kan-O
VP, Project Management



Gareth Morgan, MS, MBA
*President, Qpex Biopharma and
Associate Corporate Officer*



Simon Portsmouth, MD, FRCP
SVP, Head of Clinical Development



Joseph Scalia
SVP, Rare Disease General Manager



Sam Shum
VP, Rare Disease Operations



Andy Zylak
VP, General Manager Canada

Serving Patients Around the World



Program Overview

The RPIF Program at Shionogi is designed to be diverse and immersive, offering hands-on experience in how clinical evidence evolves into approved therapies and ultimately reaches patients through successful reimbursement and access strategies. You will spend one year embedded in the U.S. Medical Affairs team and one year integrated with the U.S. Market Access team.

Year 1: U.S. Medical Affairs Fellowship

During the Medical Affairs rotation, you will focus on developing medical strategies and education programs, data generation and dissemination and collaborating with the scientific and patient advocacy communities. You will work closely with multiple global cross-functional teams and gain tangible skills to support career growth.

Year 2: U.S. Market Access Fellowship

As part of the Market Access program, you will build a comprehensive understanding of the key market access policies impacting the pharmaceutical industry. Through engagement with Market Access colleagues, you will gain experience across a variety of areas including generating health economic data, implementing payer value propositions and executing trade and patient services account initiatives.



Meet Our Inaugural Fellow

Dhruv Modi, Pharm.D., our inaugural fellow, is spending two years with Shionogi Inc. as part of our Rare Disease Medical Affairs and U.S. Market Access teams. He joined us from Saint Joseph's University Philadelphia College of Pharmacy, where he earned a doctorate in pharmacy in May 2026.



Dhruv Modi, Pharm.D.

2026–28 Rutgers University Pharmaceutical Fellow

“This fellowship provides a unique opportunity to develop experience across both Market Access and Medical Affairs, two complementary functions that play critical roles in advancing patient care. Supporting both areas provides me with an end-to-end perspective on how a company generates evidence, communicates value and helps patients access meaningful treatments. As the first RPIF Program Fellow at Shionogi, I am grateful to join a program with strong support across the organization that aligns closely with my goal of creating meaningful impact through leadership, strategic thinking and innovation.”

U.S. Medical Affairs Executive Sponsor and Preceptor



Florin Draica, MD, MBA

Vice President, U.S. Medical Affairs

Dr. Florin Draica is Vice President, U.S. Medical Affairs at Shionogi Inc., where he oversees medical strategy, field medical, medical communications, medical information and medical operations. He has more than 22 years of experience in the biopharmaceutical industry including global, regional and country roles across multiple disease areas and various functions, including medical affairs, medical innovation and operations, and marketing.

Prior to joining Shionogi, Florin held a variety of roles at Pfizer and Solvay Pharma, including most recently serving as the U.S. Medical Affairs team Lead for Paxlovid. In this role he led the Medical and Scientific Affairs team through clinical development, regulatory and launch during a critical period of the COVID-19 pandemic. Dr. Draica is a primary care MD and holds an MBA and a certification in Medicines Development.



Yvonne Turla, Pharm.D., RUCIF

Senior Director, Medical Information

Dr. Yvonne Turla is Senior Director, Medical Information at Shionogi Inc., where she leads the U.S. Medical Information function and provides strategic leadership across Medical Affairs initiatives. With more than 15 years of biopharmaceutical industry experience, she has expertise in Medical Information, launch readiness in multiple disease areas, medical operations, digital strategy and cross-functional collaboration, helping bring scientific information to healthcare professionals and patients throughout the product lifecycle.

After completing her post-doctoral fellowship through the Rutgers Pharmaceutical Industry Fellowship program, Dr. Turla developed a passion for mentoring and developing future industry leaders. Throughout her career, she has mentored and precepted pharmacy students, interns and fellows, and has served as adjunct faculty and a preceptor for both Rutgers University and the University of Connecticut School of Pharmacy. She is committed to providing fellows with meaningful, well-rounded experiences that support their professional growth and prepare them for successful careers in the biopharmaceutical industry.

Shionogi Inc. U.S. Medical Affairs Fellowship: Year 1

You will have broad opportunities to support and/or lead a variety of Medical Affairs workstreams related to rare disease and infectious disease. Working in partnership with various geographical regions and cross-functional teams, you will contribute to various initiatives listed below:

Medical Strategy

- Support the development of Medical Affairs launch and life-cycle strategy across multiple development programs
- Participate in the planning and execution of advisory boards

Medical Communications

- Support development and approval of resources for Medical Science Liaisons (MSLs)
- Develop and execute MSL training courses
- Contribute to Medical Affairs digital strategy, including development of external- and internal-facing resources and dashboards

Medical Information

- Create, update and review medical response documents
- Share key insights with cross-functional partners
- Participate in dossier development
- Contribute to technology and digital innovation initiatives

Data Generation and Dissemination

- Support strategic publication planning, including supporting the development of posters, abstracts and manuscripts
- Contribute to the planning, execution and support of data generation activities (e.g., real-world evidence, Phase IV trials, investigator-initiated research, etc.)

Scientific Partnership

- Collaborate with the scientific community by supporting initiatives with healthcare practitioners and patient advocacy groups
- Support the development and evaluation of competitive grant programs (e.g., education, quality improvement, etc.)
- Support/lead congress planning and execution, including travel to and participation in the scientific congress

At the conclusion of the fellowship, the fellow will have obtained a variety of experiences that will prepare them for the next step in their career. These experiences may include:

- Medical Affairs pre-launch and launch strategy
- Advisory boards
- Publication planning and execution
- Data generation strategy, including development of Integrated Evidence Plans
- Congress support and attendance
- Resource development
- Medical education
- Sales/MSL training

Market Access Executive Sponsor and Preceptor



Margaret Borys

Executive Vice President and Chief Commercial Officer

Margaret Borys joined Shionogi Inc. in April 2022 as Senior Vice President and Chief Commercial Officer. In April 2024, she was promoted to Executive Vice President and Chief Commercial Officer.

Ms. Borys is a seasoned commercial leader with 30 years of experience in driving strategy, execution and operations across pharmaceutical, medical device, consumer healthcare and animal health industries. Most recently, she was the Chief Commercial Officer for a biotech startup based in Boston. Ms. Borys has held numerous executive and senior leadership positions in companies including Sanofi, Pfizer, Wyeth, Pharmacia and Arthur Andersen.

Ms. Borys is a Certified Public Accountant. She earned an MBA from Columbia Business School at Columbia University in New York and a Bachelor of Science, with highest honors, in accounting and computer science from Rutgers University in Newark, New Jersey.



Vince Cooper, Pharm.D.

Executive Director, Trade Relations and Patient Services

Dr. Vince Cooper leads Trade Relations and Patient Services at Shionogi Inc., where he is responsible for strategies and operations that support product access, distribution and patient support programs. He brings more than 25 years of experience across market access, trade relations, patient services, medical affairs and clinical operations.

Prior to joining Shionogi, Vince held leadership roles at Sanofi, where he led teams across patient support services, wholesale trade and channel management, pharmacy accounts and commercial excellence. Earlier in his career, he held positions at GlaxoSmithKline, CVS Caremark and Nova Southeastern University College of Pharmacy, with experience spanning commercial, medical and operational functions across multiple therapeutic areas. During Vince's tenure at Sanofi, he started the Market Access/Trade Rutgers fellowship program, serving as Preceptor, and ultimately became the Executive Sponsor across all of the Sanofi-Rutgers Fellows.

Shionogi Inc. Market Access Fellowship: Year 2

During the second year of the fellowship program, you will gain hands-on experience in market access and evidence generation for population decision-makers, equipping you with the skills and knowledge needed for a successful career in the pharmaceutical industry.

Evidence Generation and Value Creation

- Understand the intersection of value and price through the generation of health economic data
- Develop tools such as pre-approval information exchange (PIE) decks, budget impact models (BIMs) and Academy of Managed Care Pharmacy (AMCP) product dossiers for the health outcomes field-based team
- Collaborate with medical affairs on the development of an integrated evidence generation plan
- Work with the Health Outcome Director (HOD) field team to gain insights about payer-focused clinical teams
- Attend a payer congress to learn and understand the current landscape

Market Access Accounts, Pricing and Policy

- Gain a comprehensive understanding of the evolving U.S. drug reimbursement landscape and development of payer strategy for products across the Shionogi portfolio
- Learn how policy impacts are integrated into business development assessments, launch price and price action planning assumptions
- Acquire knowledge of government regulations, current market dynamics and competition
- Engage with key accounts in the field with the customer-facing account teams
- Develop an in-depth understanding of market access throughout a product's lifecycle, including in advance of a new product launch or in the event of an acquisition
- Gain experience in project and vendor management by engaging in cross-functional workstreams and leading various projects





Rutgers Pharmaceutical Industry Fellowship (RPIF) Program

Ernest Mario School of Pharmacy (EMSOP)

Rutgers, The State University of New Jersey

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor of EMSOP, Dr. Carolyn Seyss, the Executive Director for the Institute for Pharmaceutical Industry Fellowships, and is supported by a team of RPIF alumni experienced in the pharmaceutical industry.



**Joseph A. Barone,
PharmD, FCCP**
*Dean and Distinguished
Professor*



**Carolyn Seyss,
PharmD, RUCIF**
*Fellowship
Executive Director*



**Joseph Fulginiti,
PharmD, MBA, RUCIF**
RPIF Associate



**Erica Dankiewicz,
PharmD, RUCIF**
RPIF Consultant



**Patrick Park,
PharmD, MBA, RUCIF**
RPIF Consultant

Program History

1984

EMSOP and 2 pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically- trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the RPIF Program grew significantly and expanded to now include 26 companies within the pharmaceutical and biopharmaceutical industry with almost 300 Fellows.

2002

Dr. Ernest Mario generously provided an endowment to establish RPIF as an Institute to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Create the Fellowship structure, providing strategic leadership and administrative support
- Promote quality, communication, scholarly activity, and professional development
- Arrange specialized training opportunities within the pharmaceutical and biopharmaceutical industry

2018

RPIF expanded to offer interdisciplinary Fellows' training by adding physician Fellowship opportunities to our well-established program.

2023

The RPIF Certificate is recognized with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**.

Well over 1,900 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the sponsor companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/ commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

Key Program Features

RPIF FOSTERS the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through:

F	Family of Leading Companies Partners include several top global pharmaceutical/biopharmaceutical companies and offer large to small company environments.
O	Outstanding Alumni Track Record Well over 1,900 alumni hold prominent positions at many leading companies, including VP and C-suite levels.
S	Strong Network Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.
T	Trusted and Proven Since 1984 The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry, developing foundations for future leaders.
E	Enhanced Career Development Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.
R	Rigorous Academic Component Rutgers affiliation provides academic and professional development opportunities.

Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Rutgers, The State University of New Jersey is one of the major state university systems in the United States. EMSOP is part of Rutgers Health and is the only state school of pharmacy in New Jersey. EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey.

While RPIF offers all the benefits of a large program with an extensive network of distinguished professionals, Fellows receive the individual attention of a small program where they are known and supported as individuals.

Application Process and Eligibility Requirements

Pharmacy Fellows for the RPIF Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy from an ACPE-accredited institution before July 1 of the fellowship term.

HOW TO APPLY:

The RPIF Program is highly competitive. **Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.**

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as **Wednesday, October 14, 2026** by visiting our website at: <https://pharmafellows.rutgers.edu/how-to-apply/>

All application materials must be submitted electronically to the RPIF website per instructions on the site.

REQUIRED ITEMS:

SUBMIT BY:

Application with short-answer questions	Tuesday, October 20th
Letter of Intent (LOI)	Tuesday, October 20th
Curriculum Vitae (CV)	Tuesday, October 20th
Letters of Recommendation (LORs)	Tuesday, December 1st

ADDRESS LOI AND LORs TO:

Joseph A. Barone, PharmD, FCCP
Dean and Distinguished Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020





"My experience as an RPIF Fellow has been one of the most meaningful and transformative parts of my professional journey, providing countless opportunities for growth while reinforcing the importance of giving back to the Ernest Mario School of Pharmacy community. I am grateful to draw upon my nontraditional experiences prior to pharmacy school to mentor, support, and advocate for our RPIF Fellows, encouraging them to embrace their own unique backgrounds as strengths in their professional careers. Investing in their professional and personal development is especially rewarding because today's Fellows will become tomorrow's leaders, advancing innovations that improve the lives of patients and strengthen the communities we serve."

John (Eun Sik) Cho, PharmD
Global GMP QA Strategy



"It is hard to put into words how much this fellowship has meant to me in just my first year. RPIF has challenged me to grow, think differently, and embrace opportunities I never imagined having this early in my career. Knowing that my work has the potential to impact patient care on a global scale has been incredibly rewarding, and I am excited to see how RPIF continues to shape my career and growth as a leader. I encourage future fellows to take advantage of everything the program has to offer because the experiences you gain and the relationships you build will shape your future."

Hillary Anne Reeves, PharmD
Late-Stage Clinical Development



"I am incredibly grateful for the personal and professional growth I have experienced as a Rutgers Fellow. Through RPIF and my partner company, I have been able to learn from inspiring mentors, collaborate with talented peers, and pursue opportunities that have accelerated my development. Being surrounded by such a supportive fellowship community has made this experience especially meaningful and has helped me feel prepared and excited for the future!"

Brynn Gilbert, PharmD
Medical Communications

AIFA
Alliance of Industry Fellowship Associates

Aligned First Offer Date
December 11, 2026

The choice of a Post-Doctoral Industry Fellowship is an important decision. AIFA exists to promote a consensus first offer date for all Fellowship positions. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this AIFA-aligned offer date. Candidates should feel free to request an extension for any earlier offer to allow them to consider their options.